Ozempic 2 mg Dose for Weight Loss: Clinical Data and Patient Reports

Is the 2 mg dose a weight-loss dose?

No. Ozempic's label lists three uses, all in adults with type 2 diabetes: improving glycemic control alongside diet and exercise, reducing the risk of major adverse cardiovascular events in people with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in people with chronic kidney disease [1]. Weight loss is not among them. The semaglutide product that carries a weight-management indication is Wegovy, not Ozempic [11].

Ozempic also comes as tablets, in 1.5, 4 and 9 mg strengths. They are indicated for glycemic control in adults with type 2 diabetes and for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events [6]. The kidney indication belongs to the injection, which the label specifies for adults with type 2 diabetes and chronic kidney disease [1]. The tablets and the injection are not substitutable on a mg-for-mg basis, and there is no 2 mg tablet [6].

The 2 mg figure refers to the injection, where it is the maximum weekly dose. The label's escalation is 0.25 mg once weekly for 4 weeks, then 0.5 mg, then 1 mg if more glycemic control is needed after at least 4 weeks at 0.5 mg, then 2 mg after at least 4 weeks at 1 mg [1].

What 2 mg did in its one dedicated trial

The 2 mg dose was tested in SUSTAIN FORTE, a 40-week double-blind trial that randomized 961 adults with type 2 diabetes on metformin, with or without a sulfonylurea, whose HbA1c was 8.0% to 10.0% [2]. It compared 2 mg with 1 mg and had no placebo arm. Body weight was a secondary confirmatory endpoint, not the primary one [2].

Mean weight change was -6.9 kg on 2 mg versus -6.0 kg on 1 mg [2]. The Ozempic injection label reports HbA1c reductions of 2.1 percentage points on 2 mg and 1.9 on 1 mg; 64% versus 56% reached an HbA1c below 7% [1].

Tolerability shifted only modestly between the two doses. The label states that among the 959 patients treated with 1 mg or 2 mg, gastrointestinal adverse reactions occurred in 34% on 2 mg and 30.8% on 1 mg, and that no new safety signals were identified [1].

How 2 mg compares with the 2.4 mg used in weight trials

The weight-loss results people associate with semaglutide come from 2.4 mg once weekly.

STEP 1 randomized 1,961 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, who did not have diabetes, to 2.4 mg or placebo for 68 weeks. Mean weight change was -14.9% versus -2.4%, a treatment difference of 12.4 percentage points; 86.4% on semaglutide lost at least 5% of body weight versus 31.5% on placebo [3].

STEP 2 also lasted 68 weeks. It compared 2.4 mg, 1 mg and placebo in 1,210 adults with type 2 diabetes. Mean weight change was -9.6% on 2.4 mg versus -3.4% on placebo, and 68.8% versus 28.5% lost at least 5% [7].

SELECT, an event-driven trial in 17,604 adults with established cardiovascular disease and a BMI of 27 or higher but no diabetes, followed participants for a mean of 39.8 months; mean time receiving semaglutide 2.4 mg or placebo was 34.2 months. The composite of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% versus 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90), and mean weight change at week 104 was -9.4% versus -0.9% [8].

Newer weight data go higher than 2.4 mg. STEP UP, a 72-week trial in 1,407 adults with obesity and no diabetes, compared 7.2 mg with 2.4 mg and placebo: mean weight change was -18.7% on 7.2 mg, -15.6% on 2.4 mg and -3.9% on placebo [4].

In a separate withdrawal trial at 2.4 mg, participants who switched to placebo gained 6.9% of body weight from week 20 to week 68, while those who continued semaglutide lost a further 7.9% [9].

What the Ozempic label says to watch for

The label's warnings apply to the injection generally:

• Thyroid C-cell tumors are the boxed warning. Semaglutide caused dose- and duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it does so in humans is unknown. Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and the label names neck mass, trouble swallowing, shortness of breath and persistent hoarseness as symptoms to report [1].
• Pancreatitis: the label says to discontinue Ozempic if pancreatitis is suspected [1].
• Gallbladder disease: the label says that if cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated [1].
• Hypoglycemia: risk increases with insulin or an insulin secretagogue, and the label says reducing the dose of the sulfonylurea or insulin may be necessary [1].
• Acute kidney injury from volume depletion, usually after gastrointestinal fluid loss; the label says to monitor renal function [1].
• Severe gastrointestinal reactions. Ozempic is not recommended in patients with severe gastroparesis, and postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. The label does not state that semaglutide causes gastroparesis [1].
• Pen sharing: the label says never to share a pen between patients, even when the needle is changed, because of the risk of transmitting blood-borne infections [1].

On vision, the current US label does not list non-arteritic anterior ischemic optic neuropathy. EMA's safety committee concluded in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and recommended stopping treatment if NAION is confirmed [10].

Compounded semaglutide

Compounded semaglutide is a different regulatory product from Ozempic. FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing, and it reports dosing errors with compounded injectable semaglutide, including doses above the label [5].